Categories
Africa MENA Press Releases South Africa

YOFC Announces 2021 Annual Results

Proportion of Overseas Business Exceeds 30% for the First Time

Net Profit Reaches 710 Million Yuan, Up 30% YoY

WUHAN, China, March 30, 2022 /PRNewswire/ — Yangtze Optical Fibre and Cable Joint Stock Limited Company (hereinafter referred to as “YOFC” or “the Company”) has recently announced its consolidated results for 2021 (the “Reporting Period”). During the reporting period, operating revenue reached 9,536 million yuan, an increase of 16.0% from 2020. Net profit attributable to shareholders of the parent company stood at 710 million yuan, up 30.3% YoY.

During the reporting period, YOFC continued to optimize production efficiency and cost structure, expanded the application scenarios of new products, and consolidated its leadership in the global optical Fibre and cable markets. A point of success in terms of technological innovation defined by achieving full autonomy across the whole of the optical Fibre value chain, the Company strengthened the R&D of new optical Fibres, resulting in it being the first worldwide to roll out dispersion-flat Fibre for 5G forward transmission. In another first, the Company’s large-effective-area Fibres with ultra-low attenuation as well as its proprietary multi-core and low-mode Fibre lead globally. Furthermore, the Company’s high-end multi-mode optical Fibre is being widely used in the construction of large-scale data centers at home and abroad.

While ensuring the core advantages of the main business, YOFC has continuously accelerated the pace of diversification and achieved breakthroughs in many fields. The Company has further enhanced its portfolios for optical modules/optical devices, communication network engineering, data center wiring as well as active optical cables for consumer electronics applications, while achieving new growth in optical modules, semiconductor quartz materials and submarine communications cables. The company has further leveraged its advantages in optical modules and optical devices, to avail itself of project opportunities in the data center and communication markets, with this segment demonstrating a new jump in revenue during the reporting period.

In 2021, YOFC rolled out a roadmap focused on further differentiation of products and services to enhance international competitiveness and establish a wider presence across existing and new markets. An examination of product demand and potential profitability in several target markets, most notably in Southeast Asia, Africa and Latin America, became the basis of a plan to expand production capacity accordingly, resulting in the rapid growth of overseas business revenue. During the year, the company achieved the first milestone of the new roadmap, when business revenue ex-China reaching 310 million yuan, up 46.8% YoY and accounted for more than 30% of annual revenue for the first time. Two significant projects that contributed to reaching the milestone were communication network facilities in the Philippines and in Peru, where, in both cases, the teams in charge proved themselves capable of overcoming challenges presented by the COVID-19 pandemic and completed their construction targets on schedule. These two successes were recognized by local operators, leading to the garnering of follow-up project orders. In June 2021, the Company completed the acquisition of YOFC Poliron Indústria e Comércio de Cabos Especiais Ltda. (Poliron) in Brazil, establishing its first production facility in the region. In addition, in view of actual demand across Southeast Asia, Africa and Latin America, the Company expanded its optical Fibre and cable production capacity in Indonesia as well as its optical Fibre production capacity in Poland.

Looking forward into 2022, a year marked by both opportunities and challenges, YOFC expects to consolidate the worldwide leadership position of its main business by leveraging a need to rebalance supply and demand across the industry and to continue implementing key strategic initiatives. The Company is also planning the next stage of the globalization of operations by further enhancing the overseas production capacity portfolio, as well as reinforce overseas teams through hiring local talents, so that needs of customers can be better met by conversing with them in their native languages.

https://en.yofc.com/

Categories
Africa Asean MENA Pakistan Press Releases South Africa

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization

Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis

Risk of hospitalization or death in participants with mild to moderate COVID-19 was reduced by 66% compared to placebo in the primary efficacy analysis population and by 77% compared to placebo in participants who received treatment within three days of symptom onset

Full year and fourth quarter 2021 financial results reported; $591 million in cash and investments expected to be sufficient to fund operations into second half of 2024

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases, reported that the primary endpoints were met with statistical significance for all three indications in the company’s ongoing global Phase 2/3 clinical trials evaluating its investigational drug adintrevimab (ADG20) as a pre-and-post-exposure prophylaxis (EVADE) and treatment (STAMP) for COVID-19. EVADE and STAMP were primarily conducted during a time when pre-Omicron SARS-CoV-2 variants were dominant. Following the emergence of the Omicron variant, in a pre-specified exploratory analysis in a subset of the pre-exposure cohort, a clinically meaningful reduction in cases of symptomatic COVID-19 was observed with adintrevimab compared to placebo. Across both trials, a single intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Based on these data, Adagio plans to engage with the U.S. Food and Drug Administration (FDA) and to submit an Emergency Use Authorization (EUA) application in the second quarter of 2022 for adintrevimab for both the prevention and treatment of COVID-19.

In addition, Adagio provided an update on its ongoing Phase 1 study evaluating adintrevimab at higher doses and on research activities related to adintrevimab re-engineering and the identification of new antibodies to potentially address COVID-19 and other viruses.

“COVID-19 continues to pose significant challenges globally as waning immunity combined with the emergence of resistant variants has led to ongoing waves of disease. We believe that a suite of options – spanning prophylaxis and treatment – is needed to effectively address this virus as it continues to evolve, and these data give us confidence in the potential role adintrevimab can play in physicians’ arsenals,” said David Hering, MBA, interim chief executive officer and chief operating officer of Adagio. “Based on the data from both EVADE and STAMP, including the impacts observed in preliminary analyses from participants enrolled after the emergence of the Omicron variant, our team is initiating discussions with the FDA and preparing an EUA submission for adintrevimab. With more than one million doses of adintrevimab secured for 2022 and a solid financial position expected to take us into the second half of 2024, we are optimistic about the road ahead and the impact adintrevimab could have for the many people around the globe, particularly those at high risk with co-morbidities, who continue to need options.”

Michael Ison, M.D., M.S., professor of Medicine in the Division of Infectious Diseases and of Surgery in the Division of Organ Transplantation, Northwestern University Feinberg School of Medicine, added, “the compelling data generated on adintrevimab in both of Adagio’s clinical trials represent an important step toward further addressing the continuation of the COVID-19 pandemic. I am particularly encouraged by the consistent treatment effect observed across all three clinical settings and patient subpopulations, and the favorable safety profile, with just a single dose and convenient IM delivery for all patients. The risk-reduction in the post-exposure prophylaxis setting regardless of serostatus translates to real-world use when clinicians might not know the vaccination or prior infection status of their patients. In the STAMP trial, adintrevimab showed prevention of hospitalization and death in the face of the ‘highest-risk’ variant (Delta) to-date.”

EVADE Preliminary Data
EVADE is a global, multi-center, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating adintrevimab at the 300mg IM dose in two independent cohorts for the prevention of COVID-19. The study includes a pre-exposure prophylaxis (PrEP) cohort and a post-exposure prophylaxis (PEP) cohort. The study population is comprised of adults and adolescents at risk of SARS-CoV-2 infection due to reported recent exposure or whose circumstances placed them at increased risk of acquiring SARS-CoV-2 infection and developing symptomatic COVID-19.

In the primary efficacy analysis of the PrEP cohort, adintrevimab was associated with a lower incidence of symptomatic COVID-19 compared with placebo through month three or the emergence of Omicron, whichever was earlier (12/730, 1.6% vs. 40/703, 5.7%, respectively). The standardized risk difference was -4.0% (95% CI –6.0, -2.1; p <0.0001), demonstrating a 71% relative risk reduction in favor of adintrevimab through three months. There were five (0.7%) COVID-19 related hospitalizations in the placebo group compared to none in the adintrevimab group. In a pre-specified exploratory analysis of the PrEP cohort, which included 402 participants (196 and 206 in the adintrevimab and placebo groups, respectively) following the emergence of Omicron (BA.1), a clinically meaningful reduction in cases of symptomatic COVID-19 was observed with adintrevimab, as compared to placebo. Adintrevimab was associated with a relative risk reduction of 59% and 47% with a median follow-up duration of 56 and 77 days, respectively (nominal p <0.05).

In the primary efficacy analysis in the PEP cohort, adintrevimab met statistical significance and was associated with a lower incidence of symptomatic COVID-19 through day 28 compared with placebo (3/173, 1.7% vs. 12/175, 6.9%, respectively). The standardized risk difference was -4.9% (95% CI: -8.8, -1.0; p=0.0135), demonstrating a 75% relative risk reduction in favor of adintrevimab through 28 days. There were two (1.1%) COVID-19 related hospitalizations in the placebo group compared to none in the adintrevimab group.

In the EVADE cohorts across 1,239 adintrevimab-treated participants with a median range of follow up of 140 days for the PrEP cohort and 126 days for the PEP cohort as of the March 2, 2022, data cut off, the safety profile was similar to that of placebo. The incidence of adverse events (AEs), including serious adverse events (SAEs), was similar between adintrevimab and placebo groups. No study drug related SAEs, including deaths, were reported. The most frequently reported AEs were injection-site reactions, the majority of which were mild or moderate in severity and occurred with similar frequency in both groups.

STAMP Preliminary Data
STAMP is a global, multi-center, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating adintrevimab at the 300mg IM dose in patients with mild to moderate COVID-19 who are at high risk for disease progression. Adintrevimab was associated with a statistically significant lower incidence of COVID-19 related hospitalization or all cause death through day 29 compared with placebo (8/169, 4.7% vs. 23/167, 13.8%), with a standardized risk difference of -8.6% (95% CI: -14.65, -2.57; p=0.0052), demonstrating a 66% relative risk reduction in favor of adintrevimab. There was one death (0.6%) in the adintrevimab group, compared with six deaths (3.6%) in the placebo group through day 29. In patients treated within three days of symptom onset (adintrevimab n=91, placebo n=85), adintrevimab reduced the risk of COVID-19 hospitalization or death from any cause by 77% compared to placebo. STAMP enrolled 63 participants (29 in the adintrevimab group and 34 in the placebo group) with COVID-19 infection with the Omicron SARS-CoV-2 variant. There were two events of COVID-19 related hospitalization and no deaths through day 29 among the patients with the Omicron variant, and both events of hospitalization occurred in the placebo group.

In STAMP, across 192 adintrevimab-treated participants with a median follow up of 73 days in the adintrevimab group as of the February 2, 2022, data cut off, the incidence of AEs, including SAEs, was lower in the adintrevimab group. No study drug related SAEs, including deaths, were reported. The most frequently reported AEs were injection-site reactions, all of which were mild or moderate in severity and occurred with similar frequency in both groups.

“On behalf of the entire Adagio team, I’d like to thank the numerous investigators, clinical teams and, most importantly, the patients, families and caregivers for their participation in our clinical trials. We are encouraged by the data and look forward to submitting an EUA and discussing these results with the FDA and other regulatory authorities. Further, we are continuing our research efforts to improve adintrevimab activity against Omicron and identify antibodies targeting novel domains, which will provide potential additional product candidates to take into clinical development. Collectively, these efforts showcase the ability of our platform and expertise to discover, design and engineer novel antibodies, and execute global clinical trials, to potentially address infectious diseases,” said Ellie Hershberger, Pharm.D., chief development officer of Adagio.

Additional Development and Research Updates
Adagio continues to leverage its platform and expertise by conducting numerous efforts to address COVID-19, other coronaviruses, influenza and other infectious diseases, including:

  • Advancing a Phase 1 trial in healthy volunteers to evaluate pharmacokinetics and safety of additional higher doses of adintrevimab to supplement the data generated to date, which has evaluated doses up to 600mg IM. Preliminary safety data through two weeks post-dosing suggest a favorable safety profile at the 1200mg dose administered with IM injection or intravenously (IV).
  • Ongoing efforts to modify adintrevimab to improve binding to the Omicron subvariants (BA.1 and BA.2) in order to enhance neutralization potency while retaining the broad neutralization observed in vitro against other SARS-CoV-2 variants of concern. Re-engineered variants of ADG20 show over 100-fold improvement in binding and up to 40-fold enhanced neutralizing activity against the Omicron BA.1 variant while maintaining activity against all other variants of concern tested to date.
  • Ongoing discovery efforts to assess additional monoclonal antibodies from the company’s proprietary library of previously isolated SARS-CoV-2 antibodies for neutralization breadth and potency, which could be developed as a standalone treatment or combination therapy. Novel antibodies isolated from Omicron breakthrough infection donors have displayed in vitro activity against the 2003 SARS virus and all SARS-CoV-2 variants of concern tested to date, including the BA.1 and BA.2 variants.
  • Continuing discovery efforts to identify novel, broadly neutralizing antibodies that target epitopes both within and outside the receptor binding domain of SARS-CoV-2 and pan betacoronavirus neutralizing antibodies.

Full Year and Fourth Quarter 2021 Financial Results

  • Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities were $591.4 million as of December 31, 2021. Based on current operating plans, Adagio expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses and capital expenditure requirements into the second half of 2024.
  • R&D Expenses: Research and development (R&D) expenses, including in-process research and development expenses, were $68.4 million for the quarter ended December 31, 2021, and $190.4 million for the year ended December 31, 2021.
  • SG&A Expenses: Selling, general and administrative (SG&A) expenses were $14.7 million for the quarter ended December 31, 2021, and $36.5 million for the year ended December 31, 2021.
  • Net Loss: Net loss was $83.0 million, or $0.77 basic and diluted net loss per share, for the quarter ended December 31, 2021, and $226.8 million, or $5.32 basic and diluted net loss per share, for the year ended December 31, 2021.

About Adintrevimab
Adintrevimab (ADG20), Adagio’s lead product candidate, is designed to be a potent, broadly neutralizing antibody for both the prevention and treatment of COVID-19, including disease caused by most variants, as either a single or combination agent. Adintrevimab is being assessed in two separate Phase 2/3 clinical trials: the EVADE trial for the prevention of COVID-19 in both the post-exposure and pre-exposure settings, and the STAMP trial for the treatment of COVID-19. Preliminary data from these trials demonstrated that in the pre-Omicron population, adintrevimab met the primary endpoints across all three indications, demonstrating statistically significant and clinically meaningful efficacy. Across each of the trials, intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Adintrevimab is also being evaluated in a Phase 1 study to evaluate safety and pharmacokinetics at higher doses, and as of an interim data cut, no study drug related adverse events, serious adverse events, injection-site reactions or hypersensitivity reactions were reported across all dose levels evaluated. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. The company is developing its lead product candidate, adintrevimab, for the prevention and treatment of COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. Beyond COVID-19, Adagio is leveraging robust antibody discovery and development capabilities that have enabled expedited advancement of adintrevimab into clinical trials to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could”, “expects,” “intends,” “potential”, “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of adintrevimab, the review and analysis of data from our ongoing trials and the timing thereof, the initiation, modification and completion of studies or trials and related preparatory work, and our research and development programs; our plans related to engaging with regulatory authorities, including the timing of any regulatory submissions or applications; our pursuit of other strategies to broaden our portfolio of SARS-CoV-2 mAbs to address other SARS-CoV-2 variants of concern, including the Delta and Omicron variants; our discovery efforts to identify novel broadly neutralizing antibodies that target distinct epitopes both within and outside the receptor binding domain of SARS-CoV-2 and other beta coronaviruses; our expected cash runway; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the impacts of the COVID-19 pandemic on our business and those of our collaborators, our clinical trials and our financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, the predictability of clinical success of adintrevimab based on neutralizing activity in pre-clinical studies, variability of results in models used to predict activity against SARS-CoV-2 variants of concern, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process, including the outcome of our discussions with regulatory authorities concerning our Phase 2/3 clinical trials and the result of any emergency use application submission. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in Adagio’s Form 10-Q for the quarter ended September 30, 2021 filed with the Securities and Exchange Commission (the “SEC”), and in our other filings with the SEC, and in Adagio’s future reports to be filed with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic.  Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts
Media Contact:
Dan Budwick, 1AB
dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

ADAGIO THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share and per share amounts)

December 31,
2021 2020
Assets
Current assets:
Cash and cash equivalents $ 542,224 $ 114,988
Marketable securities 49,194
Prepaid expenses and other current assets 25,293 2,394
Total current assets 616,711 117,382
Property and equipment, net 83
Other non-current assets 3,297
Total assets $ 620,091 $ 117,382
Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)
Current liabilities:
Accounts payable $ 5,783 $ 8,153
Accrued expenses 56,277 4,919
Total current liabilities 62,060 13,072
Early-exercise liability 6 11
Other non-current liabilities 6
Total liabilities 62,072 13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C), $0.0001 par value; no shares authorized, issued and outstanding at December 31, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $0 and $169,900 at December 31, 2021 and December 31, 2020, respectively 169,548
Stockholders’ equity (deficit):
Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at December 31 2021; no shares authorized, issued and outstanding at December 31, 2020
Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 111,251,660 shares issued and 110,782,909 shares outstanding at December 31, 2021; 150,000,000 shares authorized, 28,193,240 shares
issued and 5,593,240 shares outstanding as of December 31, 2020
11 1
Treasury stock, at cost; 468,751 shares and 22,600,000 shares at December 31, 2021 and December 31, 2020, respectively (85 )
Additional paid-in capital 850,125 154
Accumulated other comprehensive loss (8 )
Accumulated deficit (292,109 ) (65,319 )
Total stockholders’ equity (deficit) 558,019 (65,249 )
Total liabilities, convertible preferred stock and stockholders’ equity (deficit) $ 620,091 $ 117,382

ADAGIO THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share amounts)

Year Ended
December 31, 2021
Period from
June 3, 2020
(Inception) to
December 31, 2020
Operating expenses:
Research and development(1) $ 182,891 $ 21,992
Acquired in-process research and development(2) 7,500 40,125
Selling, general and administrative 36,517 3,210
Total operating expenses 226,908 65,327
Loss from operations (226,908 ) (65,327 )
Other income (expense):
Other income (expense), net 118 8
Total other income (expense), net 118 8
Net loss (226,790 ) (65,319 )
Other comprehensive income (loss):
Unrealized loss on available-for-sale securities, net of tax (8 )
Comprehensive loss $ (226,798 ) $ (65,319 )
Net loss per share attributable to common stockholders, basic and diluted $ (5.32 ) $ (18.10 )
Weighted-average common shares outstanding, basic and diluted 42,621,265 3,608,491

(1)  Includes related-party amounts of $4,150 for the year ended December 31, 2021 and $595 for the period from June 3, 2020 (inception) to December 31, 2020.
(2)  Includes related-party amounts of $7,500 for the year ended December 31, 2021 and $39,915 for the period from June 3, 2020 (inception) to December 31, 2020.

Categories
Africa Asean MENA Pakistan Press Releases South Africa

Umit Ciftci Named Regional Business Development Manager for Turkey

TEMECULA, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (“Group”), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Umit Ciftci has been named Regional Business Development Manager for Turkey and the surrounding areas.

Based in Istanbul Turkey, he will be responsible for the Group’s full product line, and will report to Ole Jensen, NCE&IG GmbH Germany.

Umit received a degree in Management Engineering, which provided a solid background in engineering as well as business and finance. He has over 25 years of experience in Compressed Air working at various positions including sales engineer, marketing and business line manager in Turkey and Business Development Manager in UAE for Atlas Copco.

“Umit’s experience, as well as market and industry knowledge will be of great benefit to NCEIG GmbH, as we work to develop the potential opportunities in this market. We look forward to his positive contributions,” according to Ole Jensen, Vice President NCEIG Europe.

With this addition, Nikkiso continues their commitment to be both a global and local presence for their customers.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small-scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com

Categories
Africa Press Releases South Africa

LeddarTech revela valor da fusão e percepção de dados brutos na Automotive Tech.AD Berlin (Alemanha) de 3 a 5 de abril de 2022

Tecnologia de percepção ambiental para uma condução autônoma mais segura com detecção melhor

QUEBEC CITY, March 29, 2022 (GLOBE NEWSWIRE) — A LeddarTech®, líder global no fornecimento da tecnologia de detecção ADAS e AD mais flexível, robusta e precisa, tem o prazer de anunciar sua participação na Automotive Tech.AD Berlin no Titanic Chaussee Hotel Berlin como expositora e palestrante principal.

4-5 de abril de 2022: LeddarVision™ Demonstrator Space da LeddarTech (ao vivo e virtual)

Junte-se à equipe da LeddarTech para demonstrações reais de LeddarVision. O único software de fusão e percepção de sensores que usa fusão de dados brutos para simplificar conjuntos de sensores complexos, eliminar a dependência de hardware e fornecer aos clientes a flexibilidade de soluções de escala rápida em todos os modelos de veículos, proporcionando maior desempenho de ADAS e AD.

Conheça o CTO da LeddarTech, Pierre Olivier, pioneiro em sensoriamento com mais de 30 anos de experiência que fará apresentações nesses eventos durante a conferência:

  • Domingo, 3 de abril de 2022, 19h45 – 23h CET: Sessão Informal

Tema: O Caminho para a Automação Plena – Progresso e Desafios

  • Segunda-feira, 4 de abril de 2022, 10h – 10h30 CET: Apresentação

Tema: Tecnologia de Detecção e Percepção – Soluções que Resolvem Desafios Críticos de Detecção

Conheça a LeddarVision, uma plataforma de fusão e percepção de sensores de dados brutos que gera um modelo ambiental 3D RGBD abrangente com suporte a múltiplos sensores para configurações de câmera, radar e LiDAR. Esta solução centrada em software oferece desempenho de percepção superior por meio de planejamento de caminho, detecção de espaço livre e detecção, rastreamento e classificação aprimorados de objetos.

Sobre a Automotive Tech.AD Berlin

A Tech.AD Europe estimula você com novas ideias, conexões e inspiração. Este evento é dirigido a engenheiros e especialistas automotivos avançados de OEMs, fornecedores de soluções e institutos de pesquisa líderes com foco na aprendizagem de máquina AI +, tecnologias de percepção e sensor, arquiteturas de software e plataformas AV, testes e validação, veículos comerciais e implantação antecipada, conectividade e 5G, infraestruturas e cidades inteligentes, segurança e proteção, e muito mais. Junte-se a mais de 500 dos especialistas e executivos de veículos autônomos técnicos mais influentes em Berlim e online! Participe do evento também juntamente com a LeddarTech pessoalmente ou de forma digital registrando-se hoje mesmo no https://www.autonomous-driving-berlin.com/.

Sobre a LeddarTech

Fundada em 2007, a LeddarTech é uma empresa abrangente de sensoriamento ambiental completo, que viabiliza que os clientes resolvam desafios essenciais de sensoriamento, fusão e percepção em toda a cadeia de valor. A LeddarTech fornece soluções de percepção escaláveis econômicas de Nível 2+ ADAS ao Nível 5 de plena autonomia com LeddarVision™, uma plataforma de fusão e percepção de sensores de dados brutos que gera um modelo ambiental 3D abrangente a partir de uma variedade de tipos e configurações de sensores. A LeddarTech também dá suporte aos fabricantes LiDAR e integradores de sistemas automotivos de Nível 1-2 com o LeddarSteer™ de direção de feixe digital e o LiDAR XLRator™, uma solução para desenvolvimento LiDAR de estado sólido de grau automotivo com base na LeddarEngine™, e componentes principais de parceiros globais de semicondutores. A empresa é responsável por muitas inovações de aplicações com sensor remoto automotivos e de mobilidade avançadas, com mais de 100 tecnologias ADAS aprimoradas patenteadas (concedidas ou pendentes), e capacidade de condução autônoma.

Para mais informação sobre a LeddarTech, visite www.leddartech.com, LinkedIn, Twitter, Facebook e YouTube.

Contato:
Daniel Aitken, Vice-Presidente, Marketing Global, Comunicações e Relacionamento com o Investidor, LeddarTech Inc.
Tel.: + 1-418-653-9000 ramal 232
daniel.aitken@leddartech.com

Contato de Relações com Investidores: InvestorRelations@leddartech.com
https://investors.leddartech.com/

Os logotipos Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator e afins são marcas comerciais ou marcas comerciais registradas da LeddarTech Inc. e suas subsidiárias. Todas as outras marcas e nomes de produtos são ou podem ser marcas comerciais ou marcas comerciais registradas usadas para identificar produtos ou serviços de seus respectivos proprietários.

Categories
Africa Asean MENA Pakistan Press Releases South Africa

Gene-Editing Technologies, Fluid Mechanics Breakthroughs, and Solutions to Unfathomable Mathematical Equations Recognized by King Faisal Prize

The Prize’s 44th session awards eminent figures in each of its Arabic Language & Literature and Service to Islam categories

Riyadh, March 29, 2022 (GLOBE NEWSWIRE) — Two mathematicians and a scientist were among this year’s King Faisal Prize’s seven laureates who received their prizes on 29 March in Riyadh, Saudi Arabia, for having enriched humanity with key and invaluable achievements and discoveries, and excelled in the fields of Medicine, Science, Arabic Language & Literature, and Serving to Islam.

The Medicine Prize was awarded to Professor David Liu, Richard Merkin Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, who invented the first gene “base editor” in 2016.

This technology laid the foundation for possibly treating thousands of genetic diseases like sickle cell disease and muscular dystrophy. Professor David Liu used “base editors” in mice to correct the genetic mutation behind progeria, a rare condition characterized by premature aging, retarded development, and early death. Still, more work needs to be done before gene “base editors” can be used in humans.

Initiating a revolution in genome editing, “base editors” have received great global demand. They were distributed over 9,000 times to more than 3,000 laboratories around the world. Scientists were able to publish more than 300 papers on this technique, used in different organisms ranging from bacteria to mice.

“Base editing” is a precise genome editing method; like a genetic pencil, that rewrites DNA base letters, which cause genetic mutations and potentially genetic diseases. This technology, which is in constant development, chemically rewrites one DNA base to another by rearranging the atoms of one DNA base to resemble a different base. In 2019, Professor David Liu created with his team “prime editing” which offers more targeting flexibility and greater editing precision.

With over 75 issued U.S. patents, Professor Liu was referred to as the “Gene Corrector” by Nature magazine topping its list of “Ten People Who Mattered This Year” in 2017 and was included in the “Foreign Policy Leading Global Thinkers list”. He is also a biotech entrepreneur, cofounding “Editas Medicine”, which uses CRISPR therapies (tool for editing genomes) to “discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases”.

The Science Prize (Mathematics) was awarded jointly to Professor Martin Hairer, Chair in Probability and Stochastic Analysis at Imperial College’s Department of Mathematics, and to Professor Nader Masmoudi, a distinguished Professor of Mathematics at the New York University of Abu Dhabi and head of his Research Center on Stability, Instability and Turbulence.

Professor Martin Hairer developed the theory of regularity structures which gave a precise mathematical meaning to several equations that were previously outside the scope of mathematical analysis. He published his theory in 2014 providing tools and manuals for solving many previously incomprehensible equations called the stochastic partial differential equations (SPDEs). These equations involve chance and describe how randomness throws disorder into different phenomena like coin tossing, stock price changes, wind movement in a tunnel, or forest fire growth. He transformed the area of SPDEs by introducing fundamental new techniques and was able to solve equations like KPZ equation which describes the evolution of the boundary at which two substances meet over time.

Professor Hairer is a world leader in probability theory and analysis and has authored a monograph and over 100 research articles. His work has been distinguished with several prizes and awards, most notably the LMS Whitehead and Philip Leverhulme prizes in 2008, the Fermat prize in 2013, the Fröhlich prize and the Fields Medal in 2014, a knighthood in 2016, and the Breakthrough prize in Mathematics in 2020.

As for Professor Nader Masmoudi, he was able to unlock the mystery around many physics problems which remained unsolved for centuries. He found a flaw in “Euler’s” mathematical equations which for more than two centuries described the motions of fluids under any circumstance. He discovered that Euler’s equations do not apply to all circumstances, as previously thought, and proved that they could break or fail under certain conditions related to fluids. His work helped solve and understand many problems related to fluid-modeling like weather predictions and airplane turbulence.

For the past 20 years, Professor Masmoudi’s research has been at the forefront of Partial Differential Equations, Fluid Mechanics, and Dynamical Systems. He has been cited by more than 8000 papers for his works in pure and applied mathematics. He has been recognized with numerous awards, including the Best Scientific Paper Award in Annales de l’Institue Henri Poincaré, a Chair from the Fondation Sciences Mathematiques de Paris, The Fermat Prize, and the Chair Schlumberger from the IHES in Paris.

In addition to Medicine and Science, King Faisal Prize recognized this year the achievements of outstanding thinkers and scholars in the field of Arabic Language & Literature, and honored exemplary leaders who played a pivotal role in serving Islam, Muslims, and humanity at large.

The Arabic Language and Literature Prize about “Arabic Literature Studies in English” was awarded to Professor Suzanne Stetkevych, Chair of the Department of Arabic & Islamic Studies at Georgetown University, and to Professor Muhsin Al-Musawi, Professor of Arabic and Comparative Literary Studies at Columbia University.

Professor Suzanne Stetkevych was awarded the prize for her extensive research and work analyzing Arabic literature with unmatched depth from the pre-Islamic period to the revivalist period. Her research approach resulted in the renewal of the critical perspective and methods of studying classical Arabic poetry.

Professor Muhsin Al-Musawi received the prize for being a well-established authority in the field of Arabic literature demonstrating his encyclopedic knowledge in both classical and modern Arabic literature. His research and studies have made great impact on students and researchers in the field of Arabic studies, both in the Arab world and the West. He handled Arabic literature as a world literature.

The Service to Islam Prize was awarded to the former Tanzanian President His Excellency Ali Hassan Mwinyi and to Professor Hassan Mahmoud Al Shafei. His Excellency Ali Hassan Mwinyi actively participated in Islamic advocacy, spreading the spirit of religious tolerance, educating Muslims, and translating many Islamic resources and references into Swahili language. In parallel, Professor Hassan Mahmoud Alshafei served Islamic sciences through teaching, writing, authenticating, and translating, and has contributed to the establishment of the International Islamic University in Islamabad and the development of its colleges’ curricula.

The Islamic Studies Prize for this year on “Islamic Heritage of Al- Andalus” was withheld because the nominated works did not meet the criteria of the prize.

Since 1979, King Faisal Prize in its 5 different categories has awarded 282 laureates from 44 different nationalities who have made distinguished contributions to different sciences and causes. Each prize laureate is endowed with USD 200 thousand; a 24-carat gold medal weighing 200 grams, and a Certificate inscribed with the Laureate’s name and a summary of their work which qualified them for the prize.

Attachments

Maysa Shawwa
King Faisal Prize
00966581747005
Maysa.Shawwa@kff.com
Categories
Africa Press Releases South Africa

Synchronoss Personal Cloud Habilita o Serviço PicStorage da Kitamura

Varejista Multimídia Oferece Solução PicStorage Cloud para Milhões de Clientes

BRIDGEWATER, N.J., March 29, 2022 (GLOBE NEWSWIRE) — A Synchronoss Technologies, Inc. (“Synchronoss” ou a “Empresa”) (Nasdaq: SNCR), líder global e inovadora em nuvem, mensagens e produtos e plataformas digitais, anunciou hoje que a Kitamura, principal varejista de multimídia do Japão, lançou uma versão de marca branca na nuvem pessoal Synchronoss com o nome PicStorage.

A Kitamura é uma das principais varejistas do Japão que oferece serviços e produtos relacionados à imagem, incluindo câmeras, impressão de fotos, dublagem de vídeos, estúdio de fotos, álbuns de fotos e mais. A empresa tem mais de 1.000 lojas em todo o país, com mais de 20 milhões de visitantes pagantes a cada ano e aproximadamente 10 milhões de consumidores registrados nos seus serviços online. Com essa integração, a Kitamura poderá fornecer uma experiência online e de varejo perfeita, com a nova oferta de nuvem pessoal de marca branca.

“Além das nossas parcerias com operadoras e provedores de serviços, a Synchronoss está explorando novos aplicativos para a nossa plataforma na nuvem”, disse Yosuke Morioka, Gerente Geral da Synchronoss Japan. “Nossa colaboração com a Kitamura e o lançamento do PicStorage é apenas um exemplo de como a Synchronoss Personal Cloud pode ser aproveitada como um serviço de valor agregado em vários setores e verticais. “

A Kitamura oferecerá o PicStorage como um serviço por assinatura. Ele incluirá um aplicativo de marca e acesso a um portal online para armazenamento, gerenciamento e compartilhamento de conteúdo digital.

“O lançamento do PicStorage é uma extensão perfeita do nosso portfólio de produtos e serviços”, disse Hajime Yanagisawa, Diretor Digital e Diretor Administrativo da Kitamura. “Atualmente, milhões dos nossos clientes poderão proteger seus conteúdos digitais na nuvem e compartilhá-los com amigos e familiares. O PicStorage permite que o cliente experimente novas maneiras de organizar e curtir suas fotos e memórias. A Kitamura continuará a expandir este serviço com serviços relacionados a fotos que melhorarão a experiência do cliente.”

Além da Kitamura, a Synchronoss tem clientes nos EUA, Europa e Ásia, incluindo Verizon, AT&T, Tracfone, Assurant, Allstate Protection Plans, Telkomsel, BT, Proximus e SFR.

Sobre a Kitamura
A Kitamura é uma empresa líder em produtos e serviços fotográficos e relacionados a vídeos do Japão. A empresa possui os maiores laboratórios internos do Japão (fábricas de processamento de fotos e vídeos) e fornece seus serviços e produtos por meio de mais de 1.000 lojas de varejo em todo o país e online. A empresa tem por missão fornecer serviços para moldar as lembranças dos clientes, no presente momento e também nas próximas décadas, restaurar fotos e reviver memórias preciosas.

Sobre a Synchronoss

A Synchronoss Technologies(Nasdaq: SNCR) cria software que capacita empresas ao redor do mundo a se conectarem com seus assinantes de forma confiável e significativa. O conjunto de produtos da empresa ajuda a agilizar as redes, simplificar a integração e envolver os assinantes, permitindo novos fluxos de receita, redução dos custos e aumento da velocidade no mercado. Centenas de milhões de assinantes confiam nos produtos da Synchronoss que se mantêm em sincronia com as pessoas, serviços e conteúdo que elas gostam. É por isso que mais de 1.500 funcionários talentosos da Synchronoss em todo o mundo se esforçam todos os dias para reimaginar um mundo em sincronia. Saiba mais em www.synchronoss.com

Contato de Relações com a Mídia:
Domenick Cilea
Springboard
dcilea@springboardpr.com

Contato de Relações com Investidores:
Matt Glover / Tom Colton
Gateway Group, Inc.
SNCR@gatewayir.com

Categories
Africa Press Releases South Africa

Synchronoss Personal Cloud permet le service PicStorage de Kitamura

Le détaillant multimédia proposera la solution cloud PicStorage à des millions de clients

BRIDGEWATER, New Jersey, 29 mars 2022 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (« Synchronoss » ou la « Société ») (Nasdaq : SNCR), un leader mondial et innovateur en matière de produits et plateformes numériques, de messagerie et de cloud, a annoncé aujourd’hui que Kitamura, le principal détaillant multimédia au Japon, avait lancé une version en marque blanche du Synchronoss Personal Cloud sous la dénomination PicStorage.

Kitamura est l’un des principaux détaillants japonais proposant des services et des produits liés à l’image, y compris des appareils photo, l’impression de photos, le doublage de vidéos, un studio photo, des albums photo, etc. Le détaillant compte plus de 1 000 points de vente au détail à travers le pays, avec plus de 20 millions de visiteurs payants chaque année et environ 10 millions de consommateurs inscrits à ses services en ligne. Grâce à cette intégration, Kitamura sera en mesure de fournir des expériences de vente fluides en ligne et en magasin, avec la nouvelle offre de cloud personnel PicStorage.

« En plus de nos partenaires opérateurs et fournisseurs de services, Synchronoss explore de nouvelles applications pour notre plateforme cloud », a déclaré Yosuke Morioka, directeur général de Synchronoss Japan. « Notre collaboration avec Kitamura et son lancement de PicStorage n’est qu’un exemple de la manière dont le Synchronoss Personal Cloud peut être exploité en tant que service à valeur ajoutée dans de nombreux secteurs et marchés verticaux », a-t-il ajouté.

Kitamura proposera PicStorage en tant que service par abonnement. Celui-ci comprendra l’application de la marque et l’accès à un portail en ligne pour stocker, gérer et partager du contenu numérique.

« Le lancement de PicStorage constitue une extension parfaite pour notre portefeuille de produits et de services », a déclaré Hajime Yanagisawa, directeur informatique et directeur général de Kitamura. « Des millions de nos clients pourront désormais sauvegarder leur contenu numérique dans le cloud et le partager avec leurs amis et leur famille. PicStorage permet au client de découvrir de nouvelles façons d’organiser et de profiter de ses photos et souvenirs. Kitamura continuera d’étendre ce service avec des services liés à la photo qui amélioreront l’expérience client ».

En plus de Kitamura, Synchronoss compte des clients aux États-Unis, en Europe et en Asie, parmi lesquels Verizon, AT&T, Tracfone, Assurant, Allstate Protection Plans, Telkomsel, BT, Proximus et SFR.

À propos de Kitamura
Kitamura est une société de premier plan en produits et services de photo et vidéo au Japon. La société possède les plus grands laboratoires internes (installations de traitement de photos et vidéos) du Japon et fournit ses services et produits via plus de 1 000 magasins de détail à l’échelle nationale et en ligne. Elle s’est donné pour mission de fournir des services pour façonner les souvenirs de ses clients non seulement sur le moment, mais aussi pour les décennies à venir, permettant aussi de restaurer les photos et de raviver de précieux souvenirs.

À propos de Synchronoss

Synchronoss Technologies (Nasdaq : SNCR) est un développeur de logiciels permettant aux entreprises du monde entier de se connecter à leurs abonnés de manière fiable et pertinente. Sa gamme de produits contribue à rationaliser les réseaux, simplifier l’intégration et interagir avec les abonnés afin de créer de nouvelles sources de revenus, de réduire les coûts et d’accélérer la mise sur le marché. Plusieurs centaines de millions d’abonnés font confiance à Synchronoss pour rester en phase avec les individus, les services et les contenus qu’ils aiment. C’est pourquoi plus de 1 500 talentueux collaborateurs de Synchronoss à travers le monde s’efforcent chaque jour de repenser un monde synchrone. Pour en savoir plus, rendez-vous sur www.synchronoss.com.

Contact pour les relations avec les médias :
Domenick Cilea
Springboard
dcilea@springboardpr.com

Contact pour les relations avec les investisseurs :
Matt Glover / Tom Colton
Gateway Group, Inc.
SNCR@gatewayir.com

Categories
Politics

US Ambassador to Somalia Condemns Al-Shabab Attacks

U.S. Ambassador to Somalia Larry André has condemned a recent wave of attacks by al-Shabab militants across the country that killed more than 60 people.

Speaking to VOA Somali on Tuesday, André said the attacks in Mogadishu, Beledweyne and elsewhere were intended to prevent Somalia from moving toward stability.

“We condemn those who seek to murder and destroy,” the ambassador said. “They are stopping the revival of Somalia and they’re taking many lives in doing so. We support those who seek to build a secure, prosperous and peaceful Somalia. That is what our cooperation with the Somali authorities, with the Somali people, with Somali civil society is all aimed at.”

A daring March 23 attack by al-Shabab on Mogadishu’s heavily fortified airport killed at least seven people including five foreigners, according to Somali police spokesperson Major Abdifatah Aden Hassan.

On the same day, two deadlier explosions in Beledweyne claimed the lives of 48 more people including a female lawmaker, Amina Mohamed Abdi.

Al-Shabab attacks continued into this week as the militant group carried out a raid and roadside explosion in Puntland, killing five soldiers. Another attack on Tuesday night in the town of Wanlaweyn injured a security official and killed his teenage son.

André said stability in the Horn of Africa cannot be achieved without the revival of Somalia as a prosperous, democratic and peaceful country.

“And these acts of murder on a mass scale prevents achievement of that full revival,” he said.

On the day of the attack on Mogadishu airport, al-Shabab fired mortars at the facility.

No casualties were reported, but Andre acknowledged that one of the mortars landed close to the U.S. Embassy.

“It also came close to the United Nations compound and landed in the United Nations compound, landed in the international compound and some landed at sea,” he said.

Al-Shabab has increased attacks carried out by suicide bombers wearing vests, known as Person-Borne Improvised Explosive Devices (PBIED), a tactic the group has used for more than a decade.

The attack in Beledweyne was al-Shabab’s third PBIED attack this year, following 11 such attacks in 2020 and 13 last year.

Police say the increase in al-Shabab’s PBIED attacks is because police operations, surveillance and checkpoints have reduced the effectiveness of Vehicle-Borne Improvised Explosive Device (VBIEDs).

Andre said al-Shabab’s attacks are indiscriminate.

“They often just kill indiscriminately. That is what they do. They are murderers,” he said.

Droughts

The increased al-Shabab attacks come as Somalia tries to cope with a droughts that has killed tens of thousands of livestock and displaced tens of thousands of pastoral residents.

Somalia has declared a state of humanitarian emergency because of the drought. Aid workers are saying the situation is “catastrophic.”

“Right now, there are 4.5 million people in Somalia who are being affected by the drought,” said Tom Solomon, a senior humanitarian and development official with the U.S. Agency for International Development. “That includes 1.4 million children under the age of six, who are malnourished. And it includes 700,000 people who have left their homes in search of water and pasture for the animals.”

Although the drought has affected the entire country, the central and southern regions are among the hardest hit, with the agro-pastoralists losing their livestock because of lack of water and lack of pasture, Solomon said.

“What has happened as a result is that people don’t have enough food to eat; it’s a real crisis because the price of food has gone way up [and] the value of animals that people sell has gone down,” he said.

“We are concerned that there could be a fourth consecutive below average rainy season in Somalia with the upcoming rains. That would be unprecedented,” Solomon added.

Solomon said the United States remains a major humanitarian donor to Somalia. He said last year the U.S. provided $210 million to assist Somalia.

Source: Voice of America

Categories
Politics

Blinken Urges Algeria to Rethink Stands on Russia, Western Sahara

U.S. Secretary of State Antony Blinken wrapped up a three-nation tour of the Middle East and North Africa on Wednesday with appeals for Algeria to limit ties with Russia and look to improve relations with neighboring Morocco.

“The countries of North Africa and the Middle East have experienced themselves the consequences of Russia’s military campaigns before,” Blinken said, noting Russian interventions in Syria and Libya and the impact on energy and food security that the Ukraine conflict is having.

“The international community must increase the pressure on Russia to end this unprovoked and unjustified war,” he said.

Algerian President Abdelmadjid Tebboune has in the past referred to Russia as a “brotherly country,” and has maintained pressure on Morocco over its claim to the disputed territory of the Western Sahara, where Algeria backs independence fighters.

‘Stand with the victim’

After meeting with Tebboune, Blinken said the Ukraine conflict should cause all countries to re-evaluate relations with Russia and express their support for the territorial integrity of other states.

“I know that that’s something Algerians feel strongly about,” he said.

“There are times when one issue emerges that is so clearly black and white,” he said. “It’s important to stand with the victim and to stand with the principles that have also been violated.”

Algeria has had close ties with Russia since its independence from France in 1962 and is a major purchaser of Russian weaponry.

It is also locked in a bitter dispute with Morocco over the status of the former Spanish colony of Western Sahara. Algiers opposes a plan by Rabat to retain control of the territory while granting it semi-autonomous status.

Algerian officials provided no immediate readout of Tebboune’s meeting with Blinken.

Blinken and other U.S. officials have praised the Moroccan plan as “serious, realistic and credible” but have not explicitly endorsed it as the path to a resolution. Earlier this month, Algeria angrily recalled its ambassador to Spain after the Spanish government offered the same assessment — an enormous departure from its earlier stance of considering Morocco’s grip on Western Sahara an occupation.

Blinken did not repeat the phrase at his news conference in Algiers and instead said only that the U.S. fully supports U.N. efforts to resolve the situation.

“We’re very focused on diplomacy,” he said.

Blinken came to Algeria a day after meeting senior Moroccan officials in Rabat, where he praised Morocco’s improvements in ties with Israel.

And on Monday, Blinken had been in Israel’s Negev Desert where he and the Israeli foreign minister participated in a historic gathering with their counterparts from Arab nations, including Morocco, that have normalized relations with Israel.

‘Abraham Accords’

Morocco, along with the United Arab Emirates and Bahrain, was one of the countries to fully normalize relations with Israel during the Trump administration’s push to negotiate the so-called “Abraham Accords,” in which the U.S. pledged significant support in exchange for such recognition.

For its part, Morocco won U.S. recognition for its claim to Western Sahara in return for its agreement with Israel.

In a rare endorsement of a Trump foreign policy initiative, the Biden administration has signaled its full backing for the Abraham Accords and pledged to try to expand and strengthen them.

But, while the administration has not revoked Trump’s decision on Western Sahara, it has taken few steps to advance it, and plans to build a U.S. consulate there have not advanced since Trump announced them in 2020.

That has led to questions about whether Washington is fully on board with Moroccan sovereignty over the former Spanish colony.

Source: Voice of America

Categories
Politics

Burundi Lifts Ban on BBC After Almost 3 Years

Burundi’s media authority announced Wednesday that it would lift a nationwide ban on the British Broadcasting Corporation (BBC), nearly three years after the broadcaster was forced to stop operating in the East African country.

The National Communication Council withdrew the license for the broadcasting giant in 2019, accusing it of breaching press laws and unprofessional conduct.

“We reached the decision to reopen BBC radio starting today,” the regulator’s president, Vestine Nahimana, said.

The broadcaster had met the conditions set by the government, Nahimana said, adding that President Evariste Ndayishimiye had initiated the easing of restrictions on sanctioned news outlets.

Voice of America was suspended alongside BBC Radio in May 2018. While BBC has met the government’s conditions to broadcast, VOA has not.

The two broadcasters were suspended barely two weeks before a constitutional referendum intended to shore up the power of former President Pierre Nkurunziza and enable him to rule until 2034.

The government-controlled media regulator accused the BBC of damaging the reputation of Nkurunziza during a discussion program and said the broadcaster had ignored previous warnings.

The suspension followed a damning BBC investigation into alleged secret torture sites run by the government to silence dissent. The state denied the report, dismissing it as “fake news.”

Nkurunziza died of heart failure in June 2020.

Following Ndayishimiye’s election, Western nations including the United States and the European Union have eased sanctions on the country, crediting elections, a decrease in violence, and government reforms. But campaign groups insist human rights are still being widely abused.

Before the ban, the BBC and VOA used to broadcast daily in the national language Kirundi as well as in French and English, and drew large numbers of listeners, especially in rural areas.

Burundi is the poorest country in the world as measured by GDP per capita, at less than $240 (215 euros) in 2020, according to the World Bank.

It is ranked among the worst countries in the world for press freedom, with many local and international news outlets blacklisted and independent journalists forced into exile since a major political crisis in 2015.

Source: Voice of America